Drug Ups Effect of Gemcitabine in Pancreatic Cancer

Share this article:
Drug Ups Effect of Gemcitabine in Pancreatic Cancer
Drug Ups Effect of Gemcitabine in Pancreatic Cancer

(HealthDay News) -- The efficacy of gemcitabine in treating pancreatic cancer can be greatly improved by a second drug that increases gemcitabine levels by preventing its breakdown, according to a study published online Feb. 28 in Cancer Discovery.

Using a mouse model of pancreatic ductal adenocarcinoma, Kristopher K. Frese, Ph.D., and colleagues from the University of Cambridge in the United Kingdom, investigated the efficacy and mechanism of action of nanoparticle albumin-bound-paclitaxel combined with gemcitabine.

The researchers found that the combination treatment led to greater tumor regression and reduced tumor metastasis compared with gemcitabine alone. The increased efficacy was due to an increase in gemcitabine levels, which was due to a marked decrease in cytidine deaminase, which metabolizes gemcitabine. Paclitaxel degraded cytidine deaminase via reactive oxygen species.

"These data uncover novel insight into the antitumor activity of nanoparticle albumin-bound-paclitaxel and provide a distinct mechanism for improving gemcitabine delivery to pancreatic tumors that warrants further investigation in the clinical setting," Frese and colleagues conclude.

Paclitaxel concentrations were measured by an employee at Abraxis Bioscience.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.

Overdetection of PSA recurrence after radical prostatectomy more likely in older patients

Overdetection of PSA recurrence after radical prostatectomy more ...

For some men, prostate cancer recurrence may be overdetected, especially in those aged over 70.